Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma

Authors: Zhen Liu, Lixia Li, Zhixiong Yang, Weiren Luo, Xin Li, Huiling Yang, Kaitai Yao, Bin Wu, Weiyi Fang

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Introduction

The aim of the present study was to analyze the expression of matrix metalloproteinase 9 (MMP9) in nasopharyngeal carcinoma (NPC) and its correlation with clinicopathologic features, including the survival of patients with NPC.

Methods

Using real-time PCR, we detected the mRNA expression of MMP9 in normal nasopharyngeal tissues and nasopharyngeal carcinoma (NPC) tissues. Using immunohistochemistry analysis, we analyzed MMP9 protein expression in clinicopathologically characterized 164 NPC cases (116 male and 48 female) with age ranging from 17 to 80 years (median = 48.4 years) and 32 normal nasopharyngeal tissues. Cases with greater than or equal to 6 and less than 6 of the score value of cytoplasmic MMP9 immunostaining were regarded as high expression and low expression, respectively. The relationship between the expression levels of MMP9 and clinical features was analyzed.

Results

The expression level of MMP9 mRNA was markedly greater in NPC tissues than that in the nasopharyngeal tissues. Immunohistochemical analysis revealed that the protein expression of MMP9 detected in NPC tissues was higher than that in the nasopharyngeal tissues (P = 0.004). In addition, high levels of MMP9 protein were positively correlated with the status of lymph node metastasis (N classification) (P = 0.002) and clinical stage (P < 0.001) of NPC patients. Patients with higher MMP9 expression had a significantly shorter overall survival time than did patients with low MMP9 expression. Multivariate analysis suggested that the level of MMP9 expression was an independent prognostic indicator (P = 0.008) for the survival of patients with NPC.

Conclusion

High level of MMP9 expression is a potential unfavorable prognostic factor for patients with NPC.
Appendix
Available only for authorised users
Literature
1.
2.
Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, et al: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 2008, 6: 32-10.1186/1479-5876-6-32.CrossRefPubMedPubMedCentral
3.
Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995, 55 (12): 2548-2555.PubMed
4.
Backstrom JR, Tokes ZA: The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem. 1995, 64 (3): 1312-1318. 10.1046/j.1471-4159.1995.64031312.x.CrossRefPubMed
5.
Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT: Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008, 6: 55-10.1186/1479-5876-6-55.CrossRefPubMedPubMedCentral
6.
Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al: Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009, 219 (1): 114-122. 10.1002/path.2575.CrossRefPubMed
7.
Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N: Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 2000, 6 (10): 4064-4068.PubMed
8.
Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M: Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer. 2000, 89 (4): 715-723. 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9.CrossRefPubMed
9.
Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP: Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol. 2004, 30 (5): 560-564. 10.1016/j.ejso.2004.02.007.CrossRefPubMed
10.
Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S: Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev. 2003, 22 (2-3): 153-166. 10.1023/A:1023091214123.CrossRefPubMed
11.
Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, Iftner T, Cuenda A, Chen G: p38{gamma} MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem. 2010.
12.
Lin LF, Chuang CH, Li CF, Liao CC, Cheng CP, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM, et al: ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res. 2010, 70 (1): 192-201. 10.1158/0008-5472.CAN-09-2641.CrossRefPubMed
13.
Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S: MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 2010, 28 (1): 38-43. 10.3109/07357900802672761.CrossRefPubMed
14.
Zhao ZS, Wang YY, Ye ZY, Tao HQ: Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res. 2009, 15 (4): 589-596. 10.1007/s12253-009-9158-9.CrossRefPubMed
15.
Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX: Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008, 8: 241-10.1186/1471-2407-8-241.CrossRefPubMedPubMedCentral
16.
Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I, Zografos G: Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009, 9: 390-10.1186/1471-2407-9-390.CrossRefPubMedPubMedCentral
17.
Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS: Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007, 29 (6): 564-572. 10.1002/hed.20561.CrossRefPubMed
18.
Sakata K, Someya M, Omatsu M, Asanuma H, Hasegawa T, Ichimiya S, Hareyama M, Himi T: The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma. BMC Cancer. 2007, 7: 229-10.1186/1471-2407-7-229.CrossRefPubMedPubMedCentral
19.
Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G: Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer. 1998, 82 (5): 923-930. 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2.CrossRefPubMed
20.
Yoshizaki T, Sato H, Furukawa M, Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA. 1998, 95 (7): 3621-3626. 10.1073/pnas.95.7.3621.CrossRefPubMedPubMedCentral
21.
Sillanpaa S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma VM: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol. 2007, 104 (2): 296-303. 10.1016/j.ygyno.2006.09.004.CrossRefPubMed
22.
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM: Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004, 10 (2): 7621-7628. 10.1158/1078-0432.CCR-04-1061.CrossRefPubMed
23.
Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K: Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer. 2003, 103 (5): 647-651. 10.1002/ijc.10841.CrossRefPubMed
24.
Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S: Cancer Invest.MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 2010, 28 (1): 38-43. 10.3109/07357900802672761.CrossRefPubMed
25.
Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K: Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003, 89 (11): 2116-2121. 10.1038/sj.bjc.6601372.CrossRefPubMedPubMedCentral
26.
Li Z, Bian LJ, Li Y, Liang YJ, Liang HZ: Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract. 2009, 205 (8): 542-550. 10.1016/j.prp.2009.01.015.CrossRefPubMed
Metadata
Title
Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma
Authors
Zhen Liu
Lixia Li
Zhixiong Yang
Weiren Luo
Xin Li
Huiling Yang
Kaitai Yao
Bin Wu
Weiyi Fang
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-270

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue

Research article

Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients

Research article

The investigation of Mitogen-Activated Protein kinase Phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging

Research article

Residual γH2AX foci as an indication of lethal DNA lesions

Research article

Predictive factors of radiation-induced skin toxicity in breast cancer patients

Research article

Factors associated with use of breast cancer screening services by women aged ≥ 40 years in Korea: The Third Korea National Health and Nutrition Examination Survey 2005 (KNHANES III)

Research article

Prognostic significance of lymphangiogenesis in pharyngolaryngeal carcinoma patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits